Life Sciences Float Raises £4.5 million

Life sciences company SkinBioTherapeutics’ placing has raised gross proceeds of £4.5m including a cornerstone investment from equity investor Seneca Partners.

Dr Catherine O’Neill, chief executive of SkinBioTherapeutics, said: “Joining AIM is a significant milestone for SkinBioTherapeutics and will give us the visibility we need amongst the established global players we look to partner with. The funds raised will enable us to progress the SkinBiotix technology platform and to accelerate the clinical development of our main therapeutic candidates. This is an exciting time to be in the microbiome space, especially with regards to skin health. We have an experienced team and board, plus the financial and shareholder support to maximise this opportunity.”

See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.